Xeris Biopharma Holdings, Inc. provided revenue guidance for the full year 2024. For the year, the company expects tightening 2024 total revenue guidance to $175 million to $200 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.255 USD | +1.58% | +16.84% | -4.04% |
May. 30 | Sector Update: Health Care Stocks Higher in Afternoon Trading | MT |
May. 30 | Xeris Biopharma Says Potential Levothyroxine Injection Preferred Over Oral Formulation; Shares Rise | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-4.04% | 329M | |
+40.73% | 734B | |
+32.83% | 591B | |
-6.30% | 350B | |
+15.15% | 315B | |
+4.05% | 276B | |
+15.00% | 238B | |
+9.78% | 206B | |
-5.52% | 204B | |
+6.17% | 161B |
- Stock Market
- Equities
- XERS Stock
- News Xeris Biopharma Holdings, Inc.
- Xeris Biopharma Holdings, Inc. Provides Revenue Guidance for the Full Year 2024